Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
|Articles|December 12, 2005
Medicus International: experts in global strategy and communications
Medicus International has been successfully developing global communications for 30 years.
Advertisement
Medicus International has been successfully delivering global communications for 30 years. Our philosophy is to develop inspired strategic solutions through an understanding of market opportunity and trends, product differentiation and required target audience reach. This has established us as experts in defining global communications strategies that deliver brand success.
We believe that we have pioneered the first truly successful approach to delivering marketing solutions to international pharmaceutical clients. With dedicated client service teams based in London and New York, we have extensive experience in supporting pre-launch, launch and post-launch phases in all major therapy areas. These encompass allergy, CV disease, CNS disease (including schizophrenia and depression), diabetes, fertility, gastroenterology, infectious diseases (including HIV), oncology, osteoporosis, pain, respiratory, rheumatology, and transplantation.
Our core services include:
- Strategy development (market analyses, positioning work and communications strategy development)
- Strategic publications planning and execution
- Medical writing (supported by 40+ PhD qualified in-house medical writers)
- Opinion leader development
- Meetings inception and management
- Independent/promotional medical education
- Creative and branding
- Internal communications (including representative training materials).
As part of the Publicis Healthcare Communications Group, Medicus International is supported by the largest worldwide healthcare network, including Medicus and Discovery offices and the Saatchi & Saatchi Healthcare Group.
For further details contact
Peneli Oliver, Managing Director
Jane Smith, Director of Client Services
Or visit
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5